Pink slips have followed the green light at Entrada Therapeutics. Weeks after the FDA lifted a more than two-year-long hold, the biotech has set out plans to reduce its workforce by 20% and prioritize its clinical Duchenne muscular dystrophy (DMD) candidates and key preclinical programs.
https://www.fiercebiotech.com/biotech/entrada-lays-20-staff-weeks-after-having-fda-hold-lifted